메뉴 건너뛰기




Volumn 58, Issue 3-4, 2008, Pages 190-195

Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?

Author keywords

5 Aminosalicylate; Compliance; Mesalazine; MMX; Once daily; Therapy; Ulcerative colitis

Indexed keywords

MESALAZINE; MEZAVANT; UNCLASSIFIED DRUG;

EID: 54349091743     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.08.003     Document Type: Review
Times cited : (20)

References (41)
  • 1
    • 33645972882 scopus 로고    scopus 로고
    • Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take "toll"?
    • Lakatos P.L., Fischer S., Lakatos L., Gal I., and Papp J. Current concept on the pathogenesis of IBD: crosstalk between genetic and microbial factors. Pathogenic bacteria, altered bacterial sensing or changes in mucosal integrity take "toll"?. World J Gastroenterol 12 (2006) 1829-1840
    • (2006) World J Gastroenterol , vol.12 , pp. 1829-1840
    • Lakatos, P.L.1    Fischer, S.2    Lakatos, L.3    Gal, I.4    Papp, J.5
  • 2
    • 33750609696 scopus 로고    scopus 로고
    • Recent trends in the epidemiology of inflammatory bowel diseases: up or down?
    • Lakatos P.L. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?. World J Gastroenterol 12 (2006) 6102-6108
    • (2006) World J Gastroenterol , vol.12 , pp. 6102-6108
    • Lakatos, P.L.1
  • 4
    • 0030827118 scopus 로고    scopus 로고
    • A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis
    • Safdi M., DeMicco M., Sninsky C., Banks P., Wruble L., Deren J., et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92 (1997) 1867-1871
    • (1997) Am J Gastroenterol , vol.92 , pp. 1867-1871
    • Safdi, M.1    DeMicco, M.2    Sninsky, C.3    Banks, P.4    Wruble, L.5    Deren, J.6
  • 5
    • 33745042439 scopus 로고    scopus 로고
    • Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis
    • Sutherland L., and MacDonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2 (2006) CD000543
    • (2006) Cochrane Database Syst Rev , vol.2
    • Sutherland, L.1    MacDonald, J.K.2
  • 6
    • 0036786888 scopus 로고    scopus 로고
    • Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines
    • Ransford R.A., and Langman M.J. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the committee on safety of medicines. Gut 51 (2002) 536-539
    • (2002) Gut , vol.51 , pp. 536-539
    • Ransford, R.A.1    Langman, M.J.2
  • 7
    • 33747620510 scopus 로고    scopus 로고
    • Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence
    • Desreumaux P., and Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 24 Suppl. 1 (2006) 2-9
    • (2006) Aliment Pharmacol Ther , vol.24 , Issue.SUPPL. 1 , pp. 2-9
    • Desreumaux, P.1    Ghosh, S.2
  • 8
    • 36348930927 scopus 로고    scopus 로고
    • Delayed-release multi-matrix system (MMXTM) mesalazine in ulcerative colitis
    • McCormack P.L., Robinson D.M., and Perry C.M. Delayed-release multi-matrix system (MMXTM) mesalazine in ulcerative colitis. Drugs 67 (2007) 2635-2642
    • (2007) Drugs , vol.67 , pp. 2635-2642
    • McCormack, P.L.1    Robinson, D.M.2    Perry, C.M.3
  • 9
    • 0034798909 scopus 로고    scopus 로고
    • Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
    • Kane S.V., Cohen R.D., Aikens J.E., and Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 96 (2001) 2929-2933
    • (2001) Am J Gastroenterol , vol.96 , pp. 2929-2933
    • Kane, S.V.1    Cohen, R.D.2    Aikens, J.E.3    Hanauer, S.B.4
  • 11
    • 33847213152 scopus 로고    scopus 로고
    • A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis
    • Su C., Lewis J.D., Goldberg B., Brensinger C., and Lichtenstein G.R. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 132 (2007) 516-526
    • (2007) Gastroenterology , vol.132 , pp. 516-526
    • Su, C.1    Lewis, J.D.2    Goldberg, B.3    Brensinger, C.4    Lichtenstein, G.R.5
  • 12
    • 0033021470 scopus 로고    scopus 로고
    • Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease
    • Prakash A., and Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs 57 3 (1999) 383-408
    • (1999) Drugs , vol.57 , Issue.3 , pp. 383-408
    • Prakash, A.1    Markham, A.2
  • 13
    • 0033637218 scopus 로고    scopus 로고
    • Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis
    • Bantel H., Berg C., Vieth M., Stolte M., Kruis W., and Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 95 12 (2000) 3452-3457
    • (2000) Am J Gastroenterol , vol.95 , Issue.12 , pp. 3452-3457
    • Bantel, H.1    Berg, C.2    Vieth, M.3    Stolte, M.4    Kruis, W.5    Schulze-Osthoff, K.6
  • 14
    • 20944445862 scopus 로고    scopus 로고
    • Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma
    • Rousseaux C., Lefebvre B., Dubuquoy L., Lefebvre P., Romano O., Auwerx J., et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 201 (2005) 1205-1215
    • (2005) J Exp Med , vol.201 , pp. 1205-1215
    • Rousseaux, C.1    Lefebvre, B.2    Dubuquoy, L.3    Lefebvre, P.4    Romano, O.5    Auwerx, J.6
  • 15
    • 0037309496 scopus 로고    scopus 로고
    • Peroxysome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice
    • Osawa E., Nakajima A., Wada K., Ishimine S., Fujisawa N., Kawamori T., et al. Peroxysome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 124 (2003) 361-367
    • (2003) Gastroenterology , vol.124 , pp. 361-367
    • Osawa, E.1    Nakajima, A.2    Wada, K.3    Ishimine, S.4    Fujisawa, N.5    Kawamori, T.6
  • 18
    • 0037253045 scopus 로고    scopus 로고
    • Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis
    • Sandborn W.J., and Hanauer S.B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17 (2003) 29-42
    • (2003) Aliment Pharmacol Ther , vol.17 , pp. 29-42
    • Sandborn, W.J.1    Hanauer, S.B.2
  • 19
    • 33748648599 scopus 로고    scopus 로고
    • Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study
    • D'Haens G., Hommes D., Engels L., Baert F., van der Waaij L., Connor P., et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther 24 October 1 (7) (2006) 1087-1097
    • (2006) Aliment Pharmacol Ther , vol.24 , Issue.October 1 7 , pp. 1087-1097
    • D'Haens, G.1    Hommes, D.2    Engels, L.3    Baert, F.4    van der Waaij, L.5    Connor, P.6
  • 20
    • 54349103541 scopus 로고    scopus 로고
    • MMX™ Mesalazine: a pharmacokinetic evaluation of dose proportionality and the effect of food
    • Pierce D., Martin P., Kern M., and Homolka R. MMX™ Mesalazine: a pharmacokinetic evaluation of dose proportionality and the effect of food. Gut 56 Suppl. III (2007) A158
    • (2007) Gut , vol.56 , Issue.SUPPL. III
    • Pierce, D.1    Martin, P.2    Kern, M.3    Homolka, R.4
  • 21
    • 54349086603 scopus 로고    scopus 로고
    • Once-daily oral mesalazine (1.5 g/day or 3. 0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial
    • Dilger K., Baumgaertner E., and Thomann P. Once-daily oral mesalazine (1.5 g/day or 3. 0 g/day) does not accumulate in plasma during repeated dosing-results from a clinical trial. Gut 56 Suppl. III (2007) A150
    • (2007) Gut , vol.56 , Issue.SUPPL. III
    • Dilger, K.1    Baumgaertner, E.2    Thomann, P.3
  • 23
    • 33846242590 scopus 로고    scopus 로고
    • Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis
    • Lichtenstein G.R., Kamm M.A., Boddu P., Gubergrits N., Lyne A., Butler T., et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 5 (2007) 95-102
    • (2007) Clin Gastroenterol Hepatol , vol.5 , pp. 95-102
    • Lichtenstein, G.R.1    Kamm, M.A.2    Boddu, P.3    Gubergrits, N.4    Lyne, A.5    Butler, T.6
  • 25
    • 34250883817 scopus 로고    scopus 로고
    • MMX Multi-Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials
    • Sandborn W.J., Kamm M.A., Lichtenstein G.R., Lyne A., Butler T., and Joseph R.E. MMX Multi-Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 26 (2007) 205-215
    • (2007) Aliment Pharmacol Ther , vol.26 , pp. 205-215
    • Sandborn, W.J.1    Kamm, M.A.2    Lichtenstein, G.R.3    Lyne, A.4    Butler, T.5    Joseph, R.E.6
  • 26
    • 54349098750 scopus 로고    scopus 로고
    • MMX mesalazine therapy for active, mild-to-moderate ulcerative colitis: time to initial symptom resolution
    • Schreiber S., Karlstadt R., Barrett K., and Joseph R.E. MMX mesalazine therapy for active, mild-to-moderate ulcerative colitis: time to initial symptom resolution. Gut 56 Suppl. III (2007) A160
    • (2007) Gut , vol.56 , Issue.SUPPL. III
    • Schreiber, S.1    Karlstadt, R.2    Barrett, K.3    Joseph, R.E.4
  • 27
    • 42949096844 scopus 로고    scopus 로고
    • MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations
    • Lichtenstein G.R., Kamm M.A., Sandborn W.J., Lyne A., and Joseph R.E. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther 27 (2008) 1094-1102
    • (2008) Aliment Pharmacol Ther , vol.27 , pp. 1094-1102
    • Lichtenstein, G.R.1    Kamm, M.A.2    Sandborn, W.J.3    Lyne, A.4    Joseph, R.E.5
  • 28
    • 38749119211 scopus 로고    scopus 로고
    • ® granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis
    • ® granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis. Gastroenterology 132 Suppl. S (2007) 898
    • (2007) Gastroenterology , vol.132 , Issue.SUPPL. S , pp. 898
    • Kruis, W.1    Gorelov, A.2    Kiudelis, G.3    Racz, I.4    Pokrotnieks, J.5    Horynski, M.6
  • 29
    • 54349095259 scopus 로고    scopus 로고
    • ® Granules) in active ulcerative colitis: a combined analysis from three pivotal controlled studies
    • ® Granules) in active ulcerative colitis: a combined analysis from three pivotal controlled studies. Gut 56 Suppl. S (2007) A156
    • (2007) Gut , vol.56 , Issue.SUPPL. S
    • Kruis, W.1    Greinwald, R.2    Mueller, R.3
  • 30
    • 46349099233 scopus 로고    scopus 로고
    • Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
    • Kamm M.A., Lichtenstein G.R., Sandborn W.J., Schreiber S., Lees K., Barrett K., et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57 (2008) 893-902
    • (2008) Gut , vol.57 , pp. 893-902
    • Kamm, M.A.1    Lichtenstein, G.R.2    Sandborn, W.J.3    Schreiber, S.4    Lees, K.5    Barrett, K.6
  • 31
    • 54349121063 scopus 로고    scopus 로고
    • ® mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis: outcome in patients treated over 14-16 months
    • ® mesalamine as the sole medication for the induction and maintenance of remission of mild-to-moderate ulcerative colitis: outcome in patients treated over 14-16 months. Gastroenterology 132 Suppl. S (2007) T1297
    • (2007) Gastroenterology , vol.132 , Issue.SUPPL. S
    • Kamm, M.A.1    Hanauer, S.B.2    Lichtenstein, G.R.3    Diebold, R.4    Barrett, K.5    Karlstadt, R.G.6
  • 32
    • 0030045124 scopus 로고    scopus 로고
    • An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized placebo-controlled trial
    • The mesalamine Study Group
    • The mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized placebo-controlled trial. Ann Intern Med 124 (1996) 204-211
    • (1996) Ann Intern Med , vol.124 , pp. 204-211
  • 34
    • 54349117025 scopus 로고    scopus 로고
    • The effect of endoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to-moderate ulcerative colitis
    • Lichtenstein G.R., Diebold R., Karlstadt R.G., Barrett K., and Joseph R.E. The effect of endoscopy score at the start of 5-aminosalicylic acid therapy on long-term remission rates in patients with mild-to-moderate ulcerative colitis. Gastroenterology 132 Suppl. S (2007) T1284
    • (2007) Gastroenterology , vol.132 , Issue.SUPPL. S
    • Lichtenstein, G.R.1    Diebold, R.2    Karlstadt, R.G.3    Barrett, K.4    Joseph, R.E.5
  • 35
    • 54349111890 scopus 로고    scopus 로고
    • Relationship between time taken to induce remission of acute mild-to-moderate active ulcerative colitis with MMX TM mesalazine and subsequent long-term remission rates: results from three international combined acute and maintenance studies
    • Kamm M.A., Hanauer S.B., Diebold R., Barrett K., and Jospeh R.E. Relationship between time taken to induce remission of acute mild-to-moderate active ulcerative colitis with MMX TM mesalazine and subsequent long-term remission rates: results from three international combined acute and maintenance studies. Gut 56 Suppl. III (2007) A154
    • (2007) Gut , vol.56 , Issue.SUPPL. III
    • Kamm, M.A.1    Hanauer, S.B.2    Diebold, R.3    Barrett, K.4    Jospeh, R.E.5
  • 37
    • 61849116612 scopus 로고    scopus 로고
    • ®) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial
    • ®) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. Gut 56 (2007) OP-G-378
    • (2007) Gut , vol.56
    • Dignass, A.1    Vermeire, S.2    Adamek, H.3    Befrits, R.4    Bokemeyer, B.5    Börner, N.6
  • 38
    • 57849153149 scopus 로고    scopus 로고
    • Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study
    • Kruis W., Laimas J., Pokrotnieks J., Acute G., Mikhailova T.L., Horynski M., et al. Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology 134 Suppl. S (2008) T1124
    • (2008) Gastroenterology , vol.134 , Issue.SUPPL. S
    • Kruis, W.1    Laimas, J.2    Pokrotnieks, J.3    Acute, G.4    Mikhailova, T.L.5    Horynski, M.6
  • 39
    • 33748114138 scopus 로고    scopus 로고
    • Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis
    • Loftus E.V. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin North Am 35 (2006) 517-531
    • (2006) Gastroenterol Clin North Am , vol.35 , pp. 517-531
    • Loftus, E.V.1
  • 40
    • 33645101335 scopus 로고    scopus 로고
    • Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study
    • Lakatos L., Mester G., Erdelyi Z., David G., Pandur T., Balogh M., et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 12 (2006) 205-211
    • (2006) Inflamm Bowel Dis , vol.12 , pp. 205-211
    • Lakatos, L.1    Mester, G.2    Erdelyi, Z.3    David, G.4    Pandur, T.5    Balogh, M.6
  • 41
    • 21344446543 scopus 로고    scopus 로고
    • Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies
    • Velayos F.S., Terdiman J.P., and Walsh J.M. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 100 (2005) 1345-1353
    • (2005) Am J Gastroenterol , vol.100 , pp. 1345-1353
    • Velayos, F.S.1    Terdiman, J.P.2    Walsh, J.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.